# Relmada (RLMD) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/RLMD
## Company Profile
- Ticker: RLMD
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 4.72 USD
- Market cap: 673395231.66 USD
- Last updated: 2026-08-12
## Business Overview
### Bladder Cancer Drug-Device Company
Relmada Therapeutics develops NDV-01 for localized treatment of non-muscle invasive bladder cancer.
### NDV-01
The system delivers gemcitabine locally and continuously within the bladder, seeking durable exposure while limiting systemic toxicity.
### RESCUE Program
The Phase 3 RESCUE program will evaluate NDV-01 in second-line BCG-unresponsive disease and adjuvant intermediate-risk NMIBC.
## Why The Stock Is Moving

As of Aug 12, 2026, RLMD closed up 5.59% at $4.72. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of the Phase 3 RESCUE registrational program is targeted for mid-2026.

## Drug Assets

- NDV-01

## Recent News
- 2026-07-28 12:30 EST — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11) — Source: Relmada
- 2026-07-16 11:05 EST — [Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-a5332b5c) — Source: Relmada
- 2026-06-29 11:00 EST — [Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-joins-russell-2000-and-russell-3000-indexes-f3211c84) — Source: Relmada
- 2026-06-11 11:00 EST — [Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-cns-drug-development-veteran-michael-quirk-as-seni-41648713) — Source: Relmada
- 2026-05-28 11:00 EST — [Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-present-at-the-jefferies-global-healthcare-conference) — Source: Relmada